UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1551-1560

2016

Volltextzugriff (PDF)

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

British journal of haematology, 2012-09, Vol.158 (6), p.727-738

2012

Volltextzugriff (PDF)

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-01, Vol.19 (1), p.29-34

2019

Volltextzugriff (PDF)

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Blood, 2011-07, Vol.118 (4), p.865-873

2011

Volltextzugriff (PDF)

Development of the Histoculture Drug Response Assay (HDRA)

Methods in molecular biology (Clifton, N.J.), 2018-01, Vol.1760, p.39

2018

Volltextzugriff (PDF)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Blood, 2014-10, Vol.124 (16), p.2498-2506

2014

Volltextzugriff (PDF)

The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents

Clinical cancer research, 2003-03, Vol.9 (3), p.1136-1144

2003

Volltextzugriff (PDF)

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Blood, 2009-08, Vol.114 (8), p.1489-1497

2009

Volltextzugriff (PDF)

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

The Lancet (British edition), 2000-05, Vol.355 (9218), p.1875-1881

2000

Volltextzugriff (PDF)

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients

Bone marrow transplantation (Basingstoke), 2020-06, Vol.55 (6), p.1059-1067

2020

Volltextzugriff (PDF)

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

American journal of hematology, 2009-10, Vol.84 (10), p.650-656

2009

Volltextzugriff (PDF)

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4239-4247

2003

Volltextzugriff (PDF)

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1351-1359

2000

Volltextzugriff (PDF)

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3771-3779

2001

Volltextzugriff (PDF)

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Clinical cancer research, 2001-03, Vol.7 (3), p.478-485

2001

Volltextzugriff (PDF)

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

British journal of haematology, 2010-02, Vol.148 (4), p.562-568

2010

Volltextzugriff (PDF)

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

Annals of hematology, 2008-08, Vol.87 (8), p.623-631

2008

Volltextzugriff (PDF)

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2020-05, Vol.26 (10), p.2346-2353

2020

Volltextzugriff (PDF)

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Cancer research (Chicago, Ill.), 2021-12, Vol.81 (24), p.6273-6280

2021

Volltextzugriff (PDF)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Leukemia, 2019-07, Vol.33 (7), p.1736-1746

2019

Volltextzugriff (PDF)

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Leukemia, 2009-02, Vol.23 (2), p.215-224

2009

Volltextzugriff (PDF)

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

British journal of haematology, 2023-03, Vol.200 (6), p.722-730

2023

Volltextzugriff (PDF)

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Leukemia, 2009-09, Vol.23 (9), p.1545-1556

2009

Volltextzugriff (PDF)

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

Clinical cancer research, 2016-03, Vol.22 (6), p.1378-1384

2016

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(76)

Sprache

Englisch
(76)

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Humans
(62)
Hematology
(38)
Oncology
(34)
Biological And Medical Sciences
(33)
Female
(33)
Male
(32)
Medical Sciences
(31)
Middle Aged
(31)
Aged
(30)
Adult
(29)
Multiple Myeloma - Drug Therapy
(25)
Multiple Myeloma
(23)
Hematologic And Hematopoietic Diseases
(18)
Aged, 80 And Over
(17)
Immunodeficiencies. Immunoglobulinopathies
(16)
Immunoglobulinopathies
(16)
Immunopathology
(16)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(16)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Development of the Histoculture Drug Response Assay (HDRA)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

Aktive Filter

Suchergebnisse filtern